Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deferasirox Novartis.

James C Barton1

  • 1Southern Iron Disorders Center, Birmingham, AL 35209, USA. ironmd@dnamail.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 9, 2005
PubMed
Summary
This summary is machine-generated.

Novartis is developing deferasirox, an oral medication, to treat chronic iron overload in transfusion-dependent patients. Phase III trial data is available, with expected filings in the US and EU in early 2005.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimates of European Ancestry in U.S. Hispanics Using <i>HFE</i> p.C282Y (c.845G>A; rs1800562), a Highly Informative Autosomal Marker.

Genetic testing and molecular biomarkers·2026
Same author

Serum IgA and IgM levels in hemochromatosis probands with HFE p.C282Y homozygosity.

PloS one·2026
Same author

A Decreasing North-to-South Gradient of <i>HFE</i> p.C282Y (rs1800562) Allele Frequencies in Iberia: An Analysis of 34 Population/Control Cohorts.

Genes·2026
Same author

Mean Corpuscular Volume in <i>HFE</i> p.C282Y/p.H63D Compound Heterozygotes With High Iron Phenotypes: Clinical and Laboratory Associations.

Journal of hematology·2026
Same author

Comparisons of iron phenotypes and reports of menses, pregnancies, and live births in women with <i>HFE</i> p.C282Y homozygosity and <i>HFE</i> wt/wt.

medRxiv : the preprint server for health sciences·2026
Same author

Macrocyte subpopulations in hemochromatosis probands with HFE p.C282Y homozygosity: Clinical and laboratory associations.

The American journal of the medical sciences·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Chronic iron overload is a serious complication in patients requiring frequent blood transfusions.
  • Effective iron chelation therapy is crucial for managing this condition and preventing organ damage.

Purpose of the Study:

  • To evaluate the efficacy and safety of deferasirox, a novel oral chelating agent.
  • To assess deferasirox as a once-daily treatment for chronic iron overload.

Main Methods:

  • Phase III clinical trial involving patients with chronic iron overload.
  • Administration of deferasirox as a once-daily oral therapy.

Main Results:

  • Phase III trial data for iron overload has been released.

Related Experiment Videos

  • Deferasirox demonstrates potential as a treatment for chronic iron overload.

    • Conclusions:

    • Deferasirox shows promise as a new oral chelating agent for managing iron overload.
    • Regulatory filings are anticipated in the US and EU in the first half of 2005.